Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

However, vitamin D level decreased from baseline to the end of treatment (t = 3.26, df = 5, p < 0.05), as well as levels of parathyroid hormone (t = 2.53, df = 6, p < 0.05).Comparison of safety laboratory parameters in the course of time for per-protocol participants (n = 7)Time baseline, mean (SD)24 months, mean (SD)Changet-test t (df)p (2-tailed)Partial η2Calcium, total (mmol/l)2.40 (0.09)2.45 (0.08)2.2%− 0.97 (6)0.370.14Calcium albumin corr. (mmol/l)2.25 (0.06)2.29 (0.06)1.8%− 0.93 (6)0.390.13Phosphate (mmol/l)1.15 (0.16)1.12 (0.08)− 2.7%0.61 (5)0.570.07Creatinine (μmol/l)58.1 (12.3)60.6 (10.5)4.2%− 0.73 (6)0.490.08eGFR (crea) (ml/min)119.7 (15.0)116.7 (14.0)− 2.5%1.04 (6)0.340.15Vitamine D (μg/l)42.7 (12.4)34.5 (7.5)− 19.2%3.26 (5) < 0.050.68FSH (IE/l)1.84 (4.19)1.81 (2.26)− 1.7%0.03 (5)0.980.00Estradiol (pmol/l)98.6 (150.9)98.1 (106.8)− 0.4%0.01 (6)1.000.00Bone specific alkaline phosphatase (μg/l)8.30 (2.35)13.20 (7.80)59.0%− 1.53 (4)0.200.37Parathyroid hormone, intact (ng/l)41.9 (11.9)24.2 (10.7)− 42.2%2.53 (6) < 0.050.52

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were recruited in the in: and out-patients of the Eating Disorders Centre of the Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine of the University Hospital of Zurich.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Positive Effect of Teriparatide on Areal Bone Mineral Density in Young Women with Anorexia Nervosa: A Pilot Study

Study design awaiting verification · Calcified Tissue International · 2021

Original publication title

Positive Effect of Teriparatide on Areal Bone Mineral Density in Young Women with Anorexia Nervosa: A Pilot Study

Gabriella Milos; Hanspeter Moergeli; Cynthia Sob; Doris Wisler; Mariusz Wasila; Daniel Uebelhart; Diana Frey

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The present pilot study investigated the effect of Teriparatide 1 to 34 rh-PTH (TPT) in young women diagnosed with anorexia nervosa (AN), and markedly compromised Bone Mineral Density (BMD). Patients were included who had (i) very low BMD (defined as Z-Score <  − 2.5 or T-Score <  − 2.5 if available) in at least one of the assessed localizations (lumbar spine L1: L4, total hip, femoral neck) without any previous fragility fracture; or (ii) low bone mineral density (defined as Z-Score <  − 1.5 or T-Score <  − 1.5 if available) in at least one of the assessed localizations (lumbar spine L1: L4, total hip, femoral neck) and at least one previous fragility fracture.

Ten patients with an age range of 21 to 33 were recruited and their bone outcome was assessed after 12, 18, and 24 months. After 24 months of TPT treatment, BMD improved by 13.5% in the spine, 5.0% in the femoral neck, and 4.0% in the hip. Radius cortical bone density (− 2.6%) and radius cortical thickness (− 6.4%) decreased significantly, while in tibia there was no significant decrease. Neither in radius nor in tibia a significant change in trabecular bone parameters occurred.

During the treatment, the patients’ body weight did not increase significantly. Patients did not experience severe adverse events; only mild side effects were observed. Although these results emerged from a single-arm prospective study, it seems that AN patients with a severely compromised bone situation can benefit from TPT. Larger studies are needed to ascertain the effect of this promising substance.

Authors’ abstract

The present pilot study investigated the effect of Teriparatide 1 to 34 rh-PTH (TPT) in young women diagnosed with anorexia nervosa (AN), and markedly compromised Bone Mineral Density (BMD). Patients were included who had (i) very low BMD (defined as Z-Score <  − 2.5 or T-Score <  − 2.5 if available) in at least one of the assessed localizations (lumbar spine L1: L4, total hip, femoral neck) without any previous fragility fracture; or (ii) low bone mineral density (defined as Z-Score <  − 1.5 or T-Score <  − 1.5 if available) in at least one of the assessed localizations (lumbar spine L1: L4, total hip, femoral neck) and at least one previous fragility fracture.

Ten patients with an age range of 21 to 33 were recruited and their bone outcome was assessed after 12, 18, and 24 months. After 24 months of TPT treatment, BMD improved by 13.5% in the spine, 5.0% in the femoral neck, and 4.0% in the hip. Radius cortical bone density (− 2.6%) and radius cortical thickness (− 6.4%) decreased significantly, while in tibia there was no significant decrease. Neither in radius nor in tibia a significant change in trabecular bone parameters occurred.

During the treatment, the patients’ body weight did not increase significantly. Patients did not experience severe adverse events; only mild side effects were observed. Although these results emerged from a single-arm prospective study, it seems that AN patients with a severely compromised bone situation can benefit from TPT. Larger studies are needed to ascertain the effect of this promising substance.

Publication and source details

Original title: Positive Effect of Teriparatide on Areal Bone Mineral Density in Young Women with Anorexia Nervosa: A Pilot Study

Gabriella Milos; Hanspeter Moergeli; Cynthia Sob; Doris Wisler; Mariusz Wasila; Daniel Uebelhart; Diana Frey

Calcified Tissue International · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Lilly SwitzerlandUniversität Zürich

Open Access funding provided by Universität Zürich

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:39:52.189791+00:00

DOI: 10.1007/s00223-020-00791-3 · PMC8064940